US Stock MarketDetailed Quotes
BIOR Biora Therapeutics
- 0.6277
- +0.0207+3.41%
Close Apr 26 16:00 ET
- 0.6372
- +0.0095+1.51%
Post 19:30 ET
22.52MMarket Cap-79P/E (TTM)
0.6334High0.6018Low133.69KVolume0.6334Open0.6070Pre Close82.67KTurnover0.82%Turnover RatioLossP/E (Static)35.88MShares6.700052wk High-0.22P/B10.22MFloat Cap0.585052wk Low--Dividend TTM16.27MShs Float398.0000Historical High--Div YieldTTM5.21%Amplitude0.5850Historical Low0.6180Avg Price1Lot Size
Biora Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 26.71%-48.5M | -26.52%-13.75M | -11.48%-11.03M | 42.25%-11.62M | 52.16%-12.1M | 52.84%-66.18M | 76.73%-10.86M | 76.16%-9.9M | -9.67%-20.12M | 25.15%-25.29M |
| Net income from continuing operations | -225.27%-124.12M | -12.32%-15.41M | -1,336.33%-73.45M | -223.00%-17.81M | -26.31%-17.44M | 84.58%-38.16M | 85.22%-13.72M | 88.31%-5.11M | 92.98%-5.51M | 57.20%-13.81M |
| Operating gains losses | 307.48%48.49M | 120.20%548K | 2,737.36%48.63M | 101.60%161K | 90.21%-855K | -148.58%-23.37M | -104.49%-2.71M | -162.17%-1.84M | -550.11%-10.08M | 50.02%-8.74M |
| Depreciation and amortization | -38.81%555K | -25.95%117K | -38.12%125K | -26.22%166K | -54.35%147K | -36.88%907K | -57.64%158K | 104.04%202K | -56.73%225K | -27.64%322K |
| Other non cash items | 114.93%1.38M | -58.71%256K | 103.92%369K | 387.97%383K | 210.32%374K | -113.13%-9.25M | -94.07%620K | -382.85%-9.4M | -100.32%-133K | -102.23%-339K |
| Change In working capital | 285.31%8.62M | -130.41%-799K | -36.09%2.76M | 156.05%3.46M | 158.87%3.19M | 82.02%-4.65M | 109.54%2.63M | 149.25%4.32M | -149.47%-6.18M | -166.80%-5.42M |
| -Change in receivables | 99.76%-2K | ---12K | --0 | ---- | ---- | ---828K | --0 | ---11K | ---- | ---- |
| -Change in prepaid assets | -70.53%998K | -86.43%264K | -66.18%793K | 71.96%-831K | -62.52%772K | 142.10%3.39M | -45.06%1.95M | -14.57%2.35M | 34.47%-2.96M | 664.38%2.06M |
| -Change in payables and accrued expense | 273.16%9.51M | -181.07%-745K | 5.21%2.64M | 350.87%4.73M | 140.85%2.87M | 82.58%-5.49M | 103.12%919K | 123.35%2.51M | -118.27%-1.89M | -337.92%-7.03M |
| -Change in other current liabilities | -9.53%-1.88M | -28.57%-306K | -28.63%-674K | 10.85%-452K | -0.22%-452K | -138.98%-1.72M | 83.22%-238K | 31.14%-524K | -107.62%-507K | -627.42%-451K |
| Cash from discontinued investing activities | 0 | 0 | 0 | 0 | 0 | 106.47%1.76M | -102.32%-154K | 105.55%93K | 102.79%484K | 109.03%1.34M |
| Operating cash flow | 24.71%-48.5M | -24.75%-13.75M | -12.53%-11.03M | 40.82%-11.62M | 49.50%-12.1M | 61.54%-64.42M | 72.49%-11.02M | 77.30%-9.81M | 44.97%-19.64M | 50.67%-23.96M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 88.38%-92K | 8.33%-66K | 99.39%-1K | 91.12%-19K | 98.25%-6K | 7.37%-792K | -72K | -8,100.00%-164K | 50.00%-214K | 19.53%-342K |
| Net PPE purchase and sale | 88.38%-92K | 8.33%-66K | 99.39%-1K | 91.12%-19K | 98.25%-6K | 7.37%-792K | ---72K | -8,100.00%-164K | 50.00%-214K | 19.53%-342K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 408.46%2.44M | 3,529.17%2.47M | 99.39%-1K | 91.12%-19K | 98.25%-6K | 36.23%-792K | -134.12%-72K | 62.04%-164K | 61.65%-214K | 26.13%-342K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 321.77%30.78M | 208.19%13.92M | -92.82%-2.85M | 578.22%7.63M | 285.48%12.08M | -95.63%7.3M | -93.99%4.52M | -104.64%-1.48M | -97.01%1.13M | -85.94%3.13M |
| Net issuance payments of debt | 83,433.33%10M | --10M | --0 | --0 | --0 | 99.27%-12K | --0 | --0 | --0 | 90.24%-12K |
| Net common stock issuance | 101.21%18.14M | 98.09%5.07M | -89.09%181K | --0 | 255.30%12.88M | -80.73%9.01M | -89.04%2.56M | 5,430.00%1.66M | -90.06%1.17M | -68.82%3.63M |
| Proceeds from stock option exercised by employees | 134.19%8M | --0 | --0 | ---- | ---- | -97.28%3.42M | -92.77%3.33M | --0 | ---- | ---- |
| Net other financing activities | -4.61%-5.36M | 15.82%-1.16M | 3.41%-3.03M | -180.30%-370K | -67.08%-802K | -36.53%-5.12M | -119.26%-1.37M | 61.49%-3.14M | 81.28%-132K | 76.30%-480K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 321.77%30.78M | 208.19%13.92M | -92.82%-2.85M | 578.22%7.63M | 285.48%12.08M | -95.58%7.3M | -93.86%4.52M | -104.65%-1.48M | -97.00%1.13M | -85.90%3.13M |
| Net cash flow | ||||||||||
| Beginning cash position | -65.51%30.49M | -66.08%12.57M | -45.47%26.45M | -54.69%30.46M | -65.51%30.49M | -4.00%88.4M | -31.54%37.06M | -26.50%48.51M | 3.00%67.23M | -4.00%88.4M |
| Current changes in cash | 73.62%-15.28M | 140.19%2.64M | -21.29%-13.88M | 78.58%-4.01M | 99.89%-23K | -1,474.10%-57.91M | -119.50%-6.57M | 3.45%-11.45M | -1,573.49%-18.73M | 21.03%-21.16M |
| End cash Position | -50.10%15.21M | -50.10%15.21M | -66.08%12.57M | -45.47%26.45M | -54.69%30.46M | -65.51%30.49M | -65.51%30.49M | -31.54%37.06M | -26.50%48.51M | 3.00%67.23M |
| Free cash flow | 25.47%-48.6M | -24.54%-13.81M | -10.69%-11.04M | 41.36%-11.64M | 50.14%-12.11M | 61.26%-65.21M | 72.31%-11.09M | 76.92%-9.97M | 45.03%-19.85M | 50.40%-24.3M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg